Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Affiliation: Rheumatology Unit, Center for Molecular medicine (L8:04), Karolinska Institutet, 17176 Stockholm, Sweden.
Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.
Keywords: ICOS, ICOSL (B7RP-1), co-stimulatory molecules, autoimmune disease
Rights & PermissionsPrintExport